CD34 and neoplasm: Most markers used to investigate the effectiveness of anti-angiogenic therapies characterize terminal points of the treatment, such as microvascular density by immunohistochemistry (IHC) with anti-CD34 antibodies in tumor sections, thus no real time information of the efficacy response is available [19].